Cost-Effectiveness of 177 Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations
Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1854.2-1855
DOI: 10.2967/jnumed.126.272700 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.09.2026. Verfasst von Kritika Subramanian und 1 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
TO THE EDITOR: We read with great interest the study by Gogebakan et al. ([1][1]) regarding the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer from a U.S. perspective. The authors are to be commended for their methodology, including the
Zitieren
APA
Subramanian, K., & Osborne, J. R. (2026). Cost-Effectiveness of 177 Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations. Journal of Nuclear Medicine, 67(11), 1854.2-1855. https://doi.org/10.2967/jnumed.126.272700
Vancouver
Subramanian K, Osborne JR. Cost-Effectiveness of 177 Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations. Journal of Nuclear Medicine. 2026;67(11):1854.2-1855. doi:10.2967/jnumed.126.272700
BibTeX
@article{Subramanian2026,
author = {Subramanian, Kritika and Osborne, Joseph R},
title = {Cost-Effectiveness of 177 Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {11},
pages = {1854.2--1855},
doi = {10.2967/jnumed.126.272700}
}
EUVIMED